Avotermin

DB11955InvestigationalProtein Based Therapies

Juvista has been investigated for the treatment, prevention, and basic science of Scars, Keloid, and Cicatrix.

Mechanism: Pharmacologically active on TGF-beta receptor type-2 and TGF-beta receptor type-1
Curator reviewed
Also known as: Juvista

Resolves to

Compound

Clinical / RWD

Targets

What you can answer from here — as of July 07, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

14Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Avotermin, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.